CO5180630A1 - Nuevos analogos de 2-decarboxi-2-fosfinico prostaglandina f. - Google Patents
Nuevos analogos de 2-decarboxi-2-fosfinico prostaglandina f.Info
- Publication number
- CO5180630A1 CO5180630A1 CO00058780A CO00058780A CO5180630A1 CO 5180630 A1 CO5180630 A1 CO 5180630A1 CO 00058780 A CO00058780 A CO 00058780A CO 00058780 A CO00058780 A CO 00058780A CO 5180630 A1 CO5180630 A1 CO 5180630A1
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- decarboxi
- prostaglandina
- phosphinic
- glaucoma
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000020084 Bone disease Diseases 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/303—Cycloaliphatic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente invención se relaciona con un compuesto que tiene la siguiente estructura:<EMI FILE="00058780_1" ID="1" IMF=JPEG >en dondeR1 es H o alquilo inferior (cadena alquílica compuesta de 1 a 4 átomos carbono);R2 es H, cadena de hidrocarburo saturada o insaturada, heteroalquilo (cadena saturada o insaturada que contiene carbono y por lo menos un heteroátomo, en donde ninguno de los dos heteroátomos están adyacentes. Las cadenas heteroalquílicas contienen de 1 a 18 átomos de carbono en cadena (carbono y heteroátomos) en cadena, anillo alifático carbocíclico (anillo de hidrocarburo saturado o insaturado. Los anillos alifáticos carbocíclicos no son aromáticos. Anillos alifáticos carbocíclicos son monocíclicos o son fusionados, espiro, o sistema de anillo bicíclicos conectados. Anillos alifáticos carbocíclicos monocíclicos contienen de 4 a 7 átomos de carbono), anillo alifático heterocíclico (anillo saturado o insaturado que contiene carbono de 1 a 4 heteroátomos en el anillo), anillo aromático (sistema de anillo hidrocarburo aromático. Los anillos aromáticos son sistemas de anillo monocíclico o bicíclico fusionado. Los anillos aromáticos contienen de 5 a 10 átomos de carbono) o anillo heteroaromático (anillo aromático que contiene carbono y de 1 a 4 heteroátomos en el anillo); X es 0 o S;Y es 0, S o NH;V es alquilo C4 (cadena alquílica que tiene 4 átomos miembros de carbono) o heteroalquilo M4 (cadena heteroalquílica que tiene 4 átomos miembros);a es un enlace individual, enlace doble cis, 0 enlace doble trans, b es un enlace individual, enlace doble trans, o enlace triple;cuando a es un enlace individual, W es OH o N(R3)(OR4); en donde R3 se selecciona de H, alquilo inferior (cadena alquílica compuesta de 1 a 4 átomos carbono), o heteroalquilo inferior; en donde el alquilo inferior antes mencionado es no sustituido o sustituido con 1 a 3 sustituyentes que se seleccionan del grupo que consiste de: hidroxilo, halo, tiol, y nitrilo; y en donde el heteroalquilo inferior antes mencionado es no sustituido o sustituido con 1 a 3 sustituyentes que se seleccionan del grupo que - 2 -consiste de: hidroxilo, halo, tiol, y nitrilo; y R4 es H, alquilo inferior (cadena alquílica compuesta de 1 a 4 átomos carbono) o heteroalquilo inferior;cuando a es un enlace doble cis o enlace doble trans, W es N(OR4); en donde R4 es como se define anteriormente;Z es alquilo CI, heteroalquilo Mk, alquilo-G´ Cm, heteroalquilo-G´Mn, alquilo-G" Cp, o heteroalquilo-G" Mq;en donde I es un número entero de 3 a 7, k es un número entero de 3 a 7; m es un número entero de 0 a 5 ;n es un número entero de 2 a 5, p es un número entero de 0 a 3; q es 2 o 3; G´ es anillo alifático carbocíclico monocíclico, anillo alifático heterocíclico monocíclico, anillo aromático monocíclico o anillo heteroaromático monocíclico; G" es un anillo alifático carbocíclico bicíclico, anillo alifático heterocíclico bicíclico, anillo aromático bicíclico o anillo heteroaromático bicíclico; y cualquier sal farmacéuticamente aceptable, o amida, éster, o imida biohidrolizable de ésta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14713299P | 1999-08-04 | 1999-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5180630A1 true CO5180630A1 (es) | 2002-07-30 |
Family
ID=22520396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00058780A CO5180630A1 (es) | 1999-08-04 | 2000-08-04 | Nuevos analogos de 2-decarboxi-2-fosfinico prostaglandina f. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6372730B1 (es) |
| EP (1) | EP1202999B1 (es) |
| JP (1) | JP4846150B2 (es) |
| AT (1) | ATE243215T1 (es) |
| AU (1) | AU776375B2 (es) |
| CA (1) | CA2380326C (es) |
| CO (1) | CO5180630A1 (es) |
| DE (1) | DE60003435T2 (es) |
| ES (1) | ES2202156T3 (es) |
| IL (1) | IL147771A0 (es) |
| NO (1) | NO20020523L (es) |
| WO (1) | WO2001010873A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0008776A (pt) | 1999-03-05 | 2001-12-18 | Procter & Gamble | Análogos de prostaglandinas fp-seletivosinsaturados c16 |
| US6884858B2 (en) | 1999-10-19 | 2005-04-26 | Texas Petrochemicals Lp | Process for preparing polyolefin products |
| US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
| US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| WO2006047466A2 (en) | 2004-10-21 | 2006-05-04 | Duke University | Ophthamological drugs |
| US8916206B2 (en) | 2005-12-26 | 2014-12-23 | Ltt Bio-Pharma Co., Ltd. | Nanoparticles containing water-soluble non-peptide low-molecular weight drug |
| US20070254920A1 (en) * | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
| JP5248487B2 (ja) * | 2007-05-14 | 2013-07-31 | 株式会社Ｌｔｔバイオファーマ | 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子 |
| US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| WO2010058669A1 (ja) * | 2008-11-18 | 2010-05-27 | 株式会社Ｌｔｔバイオファーマ | 新規プロスタグランジンｅ１誘導体及びそれを封入するナノ粒子 |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| CN105319283A (zh) * | 2014-07-17 | 2016-02-10 | 上海市农药研究所 | 检测三联吡啶含量的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4171331A (en) | 1978-06-05 | 1979-10-16 | Miles Laboratories, Inc. | 1 And 2-substituted analogues of certain prostaglandins |
| US5312832A (en) | 1991-05-17 | 1994-05-17 | Allergan, Inc. | Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives |
| US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
| US5658897A (en) * | 1996-04-08 | 1997-08-19 | Allergan | Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents |
| SK3362000A3 (en) * | 1997-09-09 | 2000-10-09 | Procter & Gamble | A compound analogous to prostaglandin f and use thereof |
| TR200000673T2 (tr) * | 1997-09-09 | 2000-11-21 | The Procter & Gamble Company | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. |
| PL339212A1 (en) * | 1997-09-09 | 2000-12-04 | Procter & Gamble | Aromatic c16-c20-substituted tetrahydroprostaglandines useful as fp agonists |
| US6121253A (en) * | 1998-11-20 | 2000-09-19 | Merck Frosst Canada & Co. | Prostaglandin conjugates for treating or preventing bone disease |
-
2000
- 2000-08-01 WO PCT/US2000/020851 patent/WO2001010873A1/en active IP Right Grant
- 2000-08-01 JP JP2001515681A patent/JP4846150B2/ja not_active Expired - Fee Related
- 2000-08-01 EP EP00950904A patent/EP1202999B1/en not_active Expired - Lifetime
- 2000-08-01 CA CA002380326A patent/CA2380326C/en not_active Expired - Fee Related
- 2000-08-01 AT AT00950904T patent/ATE243215T1/de not_active IP Right Cessation
- 2000-08-01 ES ES00950904T patent/ES2202156T3/es not_active Expired - Lifetime
- 2000-08-01 IL IL14777100A patent/IL147771A0/xx unknown
- 2000-08-01 DE DE60003435T patent/DE60003435T2/de not_active Expired - Lifetime
- 2000-08-01 AU AU63933/00A patent/AU776375B2/en not_active Ceased
- 2000-08-03 US US09/632,256 patent/US6372730B1/en not_active Expired - Lifetime
- 2000-08-04 CO CO00058780A patent/CO5180630A1/es not_active Application Discontinuation
-
2002
- 2002-02-01 NO NO20020523A patent/NO20020523L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU6393300A (en) | 2001-03-05 |
| DE60003435D1 (de) | 2003-07-24 |
| WO2001010873A1 (en) | 2001-02-15 |
| AU776375B2 (en) | 2004-09-09 |
| NO20020523L (no) | 2002-04-02 |
| DE60003435T2 (de) | 2004-05-19 |
| CA2380326C (en) | 2008-03-18 |
| CA2380326A1 (en) | 2001-02-15 |
| JP4846150B2 (ja) | 2011-12-28 |
| EP1202999B1 (en) | 2003-06-18 |
| JP2003506454A (ja) | 2003-02-18 |
| ES2202156T3 (es) | 2004-04-01 |
| IL147771A0 (en) | 2002-08-14 |
| ATE243215T1 (de) | 2003-07-15 |
| NO20020523D0 (no) | 2002-02-01 |
| US6372730B1 (en) | 2002-04-16 |
| EP1202999A1 (en) | 2002-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2303764A1 (en) | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists | |
| CA2303801A1 (en) | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists | |
| TR200000670T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
| ES2202156T3 (es) | Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f. | |
| EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
| HK1076107A1 (en) | Pyrrolidine derivatives as oxytocin antagonists | |
| CA2364944A1 (en) | C16 unsaturated fp-selective prostaglandins analogs | |
| BR0008776A (pt) | Análogos de prostaglandinas fp-seletivosinsaturados c16 | |
| DE69008142D1 (de) | 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes. | |
| CA2324343A1 (en) | C11 oxymyl and hydroxylamino prostaglandins useful as medicaments | |
| CA2324590A1 (en) | C11 oxymyl and hydroxylamino prostaglandins useful as fp agonists | |
| WO2001070693A3 (en) | Difluorobutyric acid derivatives and their use as metalloprotease inhibitors | |
| AU3342899A (en) | Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them | |
| CO5271694A1 (es) | Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion | |
| EA200101109A1 (ru) | Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана | |
| DE69527854D1 (de) | Derivate substituierter amidinonaphthylester | |
| DE60005525D1 (de) | 2-aminotetraline zur behandlung von glaukom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |